Novo Nordisk A/S (NONOF)
| Market Cap | 299.09B |
| Revenue (ttm) | 43.92B |
| Net Income (ttm) | 15.16B |
| Shares Out | n/a |
| EPS (ttm) | 3.40 |
| PE Ratio | 19.73 |
| Forward PE | 16.08 |
| Dividend | 1.66 (2.41%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 284 |
| Average Volume | 40,001 |
| Open | 67.50 |
| Previous Close | 67.01 |
| Day's Range | 66.94 - 68.16 |
| 52-Week Range | 55.28 - 146.00 |
| Beta | 0.22 |
| RSI | 47.29 |
| Earnings Date | Aug 6, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
Follow-Up: Sana Biotechnology 6-Month Data, +150 % Rally, and Morgan Stanley's New Overweight Call In a public post in May, I wrote about Sana Biotechnology, Inc. (NASDAQ: SANA), a biotech that has d...
Novo Nordisk: The Market Doesn't Get It
3 To Watch Of 23 'Safer' July Dividends From 46 Fortune World's Most Admired Companies
I analyze the 50 Fortune World's Most Admired Companies, focusing on dividend-paying stocks and their yield-based investment potential. Three companies—Pfizer, BMW, and Singapore Airlines—currently me...
Why dozens of Chinese firms are joining the weight loss drugs fray
Sales of weight-loss drugs in the West have soared in recent years, driven by the approval of a new class of more effective medication, the rapid growth in obese populations owing to poor diet and lac...
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's ...
Novo Nordisks Canadian drug patent lapses, opening market for Hims & Her Health
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novos b...
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.
Stocks to Watch Wednesday: Freeport-McMoRan, UnitedHealth, Novo Nordisk
Novo Nordisk: Reclaiming Market Share
Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects due to rising global demand and a robust pipeline. Recent stock weakness is overdone; valuation models s...
Novo Nordisk submits new Wegovy dose for EU approval
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving...
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Hims & Hers Health, Inc. (NYSE: HIMS) is currently experiencing a decline in its stock price, trading lower on Monday. The company’s stock has plummeted approximately 18% over the past month, reflect...
Italy set to speed through $2.3 billion Novo Nordisk investment
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its promised 2 billion-euro ($2.34 billion) investment in a factory south of Rome.
Novo Nordisk's Sell-Off Has Gone Too Far
Notable healthcare headlines for the week: Novo Nordisk, Eli Lilly, AbbVie and Centene in focus
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key markets as it races to be among the first few to reap a windfall after patents on...
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk A/S’ (NYSE: NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy . As rival Eli Lilly and Co.’s (NYSE: LLY) Zepbound gai...
Major insurance changes are coming to GLP-1 drugs for weight loss. Heres how that could affect patients
Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CV...
Insight: How Novo Nordisk misread the US market for its weight loss sensation
Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable ...